Oral semaglutide demonstrates something formulation scientists have worked toward for decades: a peptide can sometimes be delivered through the digestive system when the dosage form is engineered around the barriers that normally prevent absorption.

The tablet does not make those barriers disappear. It combines semaglutide with salcaprozate sodium, commonly called SNAC, to create a brief and highly localized environment near the tablet as it erodes in the stomach.

Only a small fraction of the swallowed semaglutide reaches systemic circulation. That does not mean the formulation is ineffective. It means the formulation, gastric environment, and conditions studied in clinical pharmacology are inseparable from the exposure the tablet produces.